nodes	percent_of_prediction	percent_of_DWPC	metapath
Zuclopenthixol—CYP2D6—Lomustine—hematologic cancer	0.0498	0.189	CbGbCtD
Zuclopenthixol—CYP2D6—Idarubicin—hematologic cancer	0.0444	0.168	CbGbCtD
Zuclopenthixol—CYP2D6—Hydroxyurea—hematologic cancer	0.0377	0.143	CbGbCtD
Zuclopenthixol—CYP2D6—Bortezomib—hematologic cancer	0.0328	0.124	CbGbCtD
Zuclopenthixol—CYP2D6—Imatinib—hematologic cancer	0.0241	0.0912	CbGbCtD
Zuclopenthixol—CYP2D6—Nilotinib—hematologic cancer	0.0219	0.0829	CbGbCtD
Zuclopenthixol—CYP2D6—Vinorelbine—hematologic cancer	0.0217	0.0822	CbGbCtD
Zuclopenthixol—CYP2D6—Vinblastine—hematologic cancer	0.0134	0.0506	CbGbCtD
Zuclopenthixol—CYP2D6—Dexamethasone—hematologic cancer	0.00989	0.0375	CbGbCtD
Zuclopenthixol—CYP2D6—Doxorubicin—hematologic cancer	0.00821	0.0311	CbGbCtD
Zuclopenthixol—Quetiapine—H1F0—hematologic cancer	0.000964	0.171	CrCbGaD
Zuclopenthixol—Clozapine—H1F0—hematologic cancer	0.000829	0.147	CrCbGaD
Zuclopenthixol—Thioproperazine—SLC22A1—hematologic cancer	0.00052	0.0924	CrCbGaD
Zuclopenthixol—Pipotiazine—SLC22A1—hematologic cancer	0.000511	0.0909	CrCbGaD
Zuclopenthixol—Thiothixene—SLC22A1—hematologic cancer	0.000511	0.0909	CrCbGaD
Zuclopenthixol—Flupentixol—ABCB1—hematologic cancer	0.000307	0.0546	CrCbGaD
Zuclopenthixol—Chlorpromazine—SLC22A1—hematologic cancer	0.000277	0.0493	CrCbGaD
Zuclopenthixol—Domperidone—ABCB1—hematologic cancer	0.000206	0.0367	CrCbGaD
Zuclopenthixol—Nefazodone—ABCB1—hematologic cancer	0.000171	0.0305	CrCbGaD
Zuclopenthixol—Trazodone—ABCB1—hematologic cancer	0.000159	0.0282	CrCbGaD
Zuclopenthixol—Thioproperazine—ALB—hematologic cancer	0.000158	0.0281	CrCbGaD
Zuclopenthixol—Pipotiazine—ALB—hematologic cancer	0.000156	0.0277	CrCbGaD
Zuclopenthixol—Thiothixene—ALB—hematologic cancer	0.000156	0.0277	CrCbGaD
Zuclopenthixol—Fluphenazine—ABCB1—hematologic cancer	0.000128	0.0228	CrCbGaD
Zuclopenthixol—Chlorprothixene—ABCB1—hematologic cancer	0.000117	0.0208	CrCbGaD
Zuclopenthixol—Trifluoperazine—ABCB1—hematologic cancer	0.000103	0.0183	CrCbGaD
Zuclopenthixol—Quetiapine—ABCB1—hematologic cancer	9.96e-05	0.0177	CrCbGaD
Zuclopenthixol—Clozapine—ABCB1—hematologic cancer	8.57e-05	0.0152	CrCbGaD
Zuclopenthixol—Chlorpromazine—ALB—hematologic cancer	8.44e-05	0.015	CrCbGaD
Zuclopenthixol—Chlorpromazine—ABCB1—hematologic cancer	8.06e-05	0.0143	CrCbGaD
Zuclopenthixol—Decreased appetite—Betamethasone—hematologic cancer	7.07e-05	0.00012	CcSEcCtD
Zuclopenthixol—Nausea—Mitoxantrone—hematologic cancer	7.06e-05	0.00012	CcSEcCtD
Zuclopenthixol—Nausea—Irinotecan—hematologic cancer	7.06e-05	0.00012	CcSEcCtD
Zuclopenthixol—Immune system disorder—Epirubicin—hematologic cancer	7.05e-05	0.00012	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Betamethasone—hematologic cancer	7.02e-05	0.00012	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	7.02e-05	0.00012	CcSEcCtD
Zuclopenthixol—Fatigue—Dexamethasone—hematologic cancer	7.01e-05	0.000119	CcSEcCtD
Zuclopenthixol—Fatigue—Betamethasone—hematologic cancer	7.01e-05	0.000119	CcSEcCtD
Zuclopenthixol—Pruritus—Etoposide—hematologic cancer	6.99e-05	0.000119	CcSEcCtD
Zuclopenthixol—Shock—Prednisone—hematologic cancer	6.97e-05	0.000119	CcSEcCtD
Zuclopenthixol—Arrhythmia—Epirubicin—hematologic cancer	6.97e-05	0.000119	CcSEcCtD
Zuclopenthixol—Pain—Betamethasone—hematologic cancer	6.96e-05	0.000118	CcSEcCtD
Zuclopenthixol—Pain—Dexamethasone—hematologic cancer	6.96e-05	0.000118	CcSEcCtD
Zuclopenthixol—Visual impairment—Doxorubicin—hematologic cancer	6.96e-05	0.000118	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Prednisone—hematologic cancer	6.95e-05	0.000118	CcSEcCtD
Zuclopenthixol—Tachycardia—Prednisone—hematologic cancer	6.92e-05	0.000118	CcSEcCtD
Zuclopenthixol—Skin disorder—Prednisone—hematologic cancer	6.88e-05	0.000117	CcSEcCtD
Zuclopenthixol—Nausea—Gemcitabine—hematologic cancer	6.88e-05	0.000117	CcSEcCtD
Zuclopenthixol—Vomiting—Cisplatin—hematologic cancer	6.86e-05	0.000117	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Prednisone—hematologic cancer	6.85e-05	0.000117	CcSEcCtD
Zuclopenthixol—Vision blurred—Methotrexate—hematologic cancer	6.84e-05	0.000116	CcSEcCtD
Zuclopenthixol—Mental disorder—Epirubicin—hematologic cancer	6.83e-05	0.000116	CcSEcCtD
Zuclopenthixol—Rash—Cisplatin—hematologic cancer	6.8e-05	0.000116	CcSEcCtD
Zuclopenthixol—Dermatitis—Cisplatin—hematologic cancer	6.8e-05	0.000116	CcSEcCtD
Zuclopenthixol—Malnutrition—Epirubicin—hematologic cancer	6.79e-05	0.000116	CcSEcCtD
Zuclopenthixol—Erythema—Epirubicin—hematologic cancer	6.79e-05	0.000116	CcSEcCtD
Zuclopenthixol—Diarrhoea—Etoposide—hematologic cancer	6.76e-05	0.000115	CcSEcCtD
Zuclopenthixol—Anorexia—Prednisone—hematologic cancer	6.75e-05	0.000115	CcSEcCtD
Zuclopenthixol—Eye disorder—Doxorubicin—hematologic cancer	6.74e-05	0.000115	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Methotrexate—hematologic cancer	6.73e-05	0.000115	CcSEcCtD
Zuclopenthixol—Tinnitus—Doxorubicin—hematologic cancer	6.73e-05	0.000115	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Dexamethasone—hematologic cancer	6.7e-05	0.000114	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Betamethasone—hematologic cancer	6.7e-05	0.000114	CcSEcCtD
Zuclopenthixol—Cardiac disorder—Doxorubicin—hematologic cancer	6.7e-05	0.000114	CcSEcCtD
Zuclopenthixol—Flatulence—Epirubicin—hematologic cancer	6.69e-05	0.000114	CcSEcCtD
Zuclopenthixol—Tension—Epirubicin—hematologic cancer	6.66e-05	0.000113	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Betamethasone—hematologic cancer	6.65e-05	0.000113	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Dexamethasone—hematologic cancer	6.65e-05	0.000113	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Triamcinolone—hematologic cancer	6.61e-05	0.000112	CcSEcCtD
Zuclopenthixol—Nervousness—Epirubicin—hematologic cancer	6.59e-05	0.000112	CcSEcCtD
Zuclopenthixol—Angiopathy—Doxorubicin—hematologic cancer	6.55e-05	0.000111	CcSEcCtD
Zuclopenthixol—Malaise—Methotrexate—hematologic cancer	6.54e-05	0.000111	CcSEcCtD
Zuclopenthixol—Dizziness—Etoposide—hematologic cancer	6.54e-05	0.000111	CcSEcCtD
Zuclopenthixol—Immune system disorder—Doxorubicin—hematologic cancer	6.52e-05	0.000111	CcSEcCtD
Zuclopenthixol—Vertigo—Methotrexate—hematologic cancer	6.52e-05	0.000111	CcSEcCtD
Zuclopenthixol—Leukopenia—Methotrexate—hematologic cancer	6.49e-05	0.000111	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Prednisone—hematologic cancer	6.46e-05	0.00011	CcSEcCtD
Zuclopenthixol—Dizziness—Prednisolone—hematologic cancer	6.45e-05	0.00011	CcSEcCtD
Zuclopenthixol—Arrhythmia—Doxorubicin—hematologic cancer	6.45e-05	0.00011	CcSEcCtD
Zuclopenthixol—Asthenia—Triamcinolone—hematologic cancer	6.43e-05	0.000109	CcSEcCtD
Zuclopenthixol—Body temperature increased—Dexamethasone—hematologic cancer	6.43e-05	0.000109	CcSEcCtD
Zuclopenthixol—Abdominal pain—Dexamethasone—hematologic cancer	6.43e-05	0.000109	CcSEcCtD
Zuclopenthixol—Body temperature increased—Betamethasone—hematologic cancer	6.43e-05	0.000109	CcSEcCtD
Zuclopenthixol—Abdominal pain—Betamethasone—hematologic cancer	6.43e-05	0.000109	CcSEcCtD
Zuclopenthixol—Nausea—Cisplatin—hematologic cancer	6.41e-05	0.000109	CcSEcCtD
Zuclopenthixol—Insomnia—Prednisone—hematologic cancer	6.41e-05	0.000109	CcSEcCtD
Zuclopenthixol—Vision blurred—Epirubicin—hematologic cancer	6.4e-05	0.000109	CcSEcCtD
Zuclopenthixol—Paraesthesia—Prednisone—hematologic cancer	6.36e-05	0.000108	CcSEcCtD
Zuclopenthixol—Pruritus—Triamcinolone—hematologic cancer	6.34e-05	0.000108	CcSEcCtD
Zuclopenthixol—Mental disorder—Doxorubicin—hematologic cancer	6.32e-05	0.000108	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Epirubicin—hematologic cancer	6.3e-05	0.000107	CcSEcCtD
Zuclopenthixol—Convulsion—Methotrexate—hematologic cancer	6.29e-05	0.000107	CcSEcCtD
Zuclopenthixol—Vomiting—Etoposide—hematologic cancer	6.29e-05	0.000107	CcSEcCtD
Zuclopenthixol—Malnutrition—Doxorubicin—hematologic cancer	6.28e-05	0.000107	CcSEcCtD
Zuclopenthixol—Erythema—Doxorubicin—hematologic cancer	6.28e-05	0.000107	CcSEcCtD
Zuclopenthixol—Agitation—Epirubicin—hematologic cancer	6.24e-05	0.000106	CcSEcCtD
Zuclopenthixol—Dyspepsia—Prednisone—hematologic cancer	6.24e-05	0.000106	CcSEcCtD
Zuclopenthixol—Rash—Etoposide—hematologic cancer	6.23e-05	0.000106	CcSEcCtD
Zuclopenthixol—Dermatitis—Etoposide—hematologic cancer	6.23e-05	0.000106	CcSEcCtD
Zuclopenthixol—Headache—Etoposide—hematologic cancer	6.19e-05	0.000105	CcSEcCtD
Zuclopenthixol—Flatulence—Doxorubicin—hematologic cancer	6.19e-05	0.000105	CcSEcCtD
Zuclopenthixol—Myalgia—Methotrexate—hematologic cancer	6.18e-05	0.000105	CcSEcCtD
Zuclopenthixol—Tension—Doxorubicin—hematologic cancer	6.17e-05	0.000105	CcSEcCtD
Zuclopenthixol—Decreased appetite—Prednisone—hematologic cancer	6.16e-05	0.000105	CcSEcCtD
Zuclopenthixol—Rash—Prednisolone—hematologic cancer	6.15e-05	0.000105	CcSEcCtD
Zuclopenthixol—Dermatitis—Prednisolone—hematologic cancer	6.14e-05	0.000105	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	6.13e-05	0.000104	CcSEcCtD
Zuclopenthixol—Malaise—Epirubicin—hematologic cancer	6.12e-05	0.000104	CcSEcCtD
Zuclopenthixol—Fatigue—Prednisone—hematologic cancer	6.11e-05	0.000104	CcSEcCtD
Zuclopenthixol—Headache—Prednisolone—hematologic cancer	6.11e-05	0.000104	CcSEcCtD
Zuclopenthixol—Discomfort—Methotrexate—hematologic cancer	6.1e-05	0.000104	CcSEcCtD
Zuclopenthixol—Nervousness—Doxorubicin—hematologic cancer	6.1e-05	0.000104	CcSEcCtD
Zuclopenthixol—Vertigo—Epirubicin—hematologic cancer	6.1e-05	0.000104	CcSEcCtD
Zuclopenthixol—Syncope—Epirubicin—hematologic cancer	6.09e-05	0.000104	CcSEcCtD
Zuclopenthixol—Leukopenia—Epirubicin—hematologic cancer	6.08e-05	0.000103	CcSEcCtD
Zuclopenthixol—Constipation—Prednisone—hematologic cancer	6.06e-05	0.000103	CcSEcCtD
Zuclopenthixol—Palpitations—Epirubicin—hematologic cancer	6e-05	0.000102	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Epirubicin—hematologic cancer	5.97e-05	0.000102	CcSEcCtD
Zuclopenthixol—Dizziness—Triamcinolone—hematologic cancer	5.93e-05	0.000101	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Methotrexate—hematologic cancer	5.92e-05	0.000101	CcSEcCtD
Zuclopenthixol—Vision blurred—Doxorubicin—hematologic cancer	5.92e-05	0.000101	CcSEcCtD
Zuclopenthixol—Convulsion—Epirubicin—hematologic cancer	5.88e-05	0.0001	CcSEcCtD
Zuclopenthixol—Nausea—Etoposide—hematologic cancer	5.87e-05	9.99e-05	CcSEcCtD
Zuclopenthixol—Hypertension—Epirubicin—hematologic cancer	5.86e-05	9.98e-05	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Prednisone—hematologic cancer	5.84e-05	9.94e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Betamethasone—hematologic cancer	5.84e-05	9.94e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Dexamethasone—hematologic cancer	5.84e-05	9.94e-05	CcSEcCtD
Zuclopenthixol—Ill-defined disorder—Doxorubicin—hematologic cancer	5.83e-05	9.92e-05	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Methotrexate—hematologic cancer	5.81e-05	9.88e-05	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Methotrexate—hematologic cancer	5.8e-05	9.87e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Prednisone—hematologic cancer	5.79e-05	9.86e-05	CcSEcCtD
Zuclopenthixol—Nausea—Prednisolone—hematologic cancer	5.79e-05	9.86e-05	CcSEcCtD
Zuclopenthixol—Myalgia—Epirubicin—hematologic cancer	5.78e-05	9.84e-05	CcSEcCtD
Zuclopenthixol—Agitation—Doxorubicin—hematologic cancer	5.77e-05	9.83e-05	CcSEcCtD
Zuclopenthixol—Anxiety—Epirubicin—hematologic cancer	5.76e-05	9.8e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Dexamethasone—hematologic cancer	5.76e-05	9.8e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Betamethasone—hematologic cancer	5.76e-05	9.8e-05	CcSEcCtD
Zuclopenthixol—Skin disorder—Methotrexate—hematologic cancer	5.75e-05	9.79e-05	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	5.74e-05	9.77e-05	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Methotrexate—hematologic cancer	5.72e-05	9.74e-05	CcSEcCtD
Zuclopenthixol—Discomfort—Epirubicin—hematologic cancer	5.71e-05	9.72e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Triamcinolone—hematologic cancer	5.7e-05	9.7e-05	CcSEcCtD
Zuclopenthixol—Malaise—Doxorubicin—hematologic cancer	5.67e-05	9.64e-05	CcSEcCtD
Zuclopenthixol—Rash—Triamcinolone—hematologic cancer	5.65e-05	9.62e-05	CcSEcCtD
Zuclopenthixol—Dry mouth—Epirubicin—hematologic cancer	5.65e-05	9.62e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Triamcinolone—hematologic cancer	5.65e-05	9.61e-05	CcSEcCtD
Zuclopenthixol—Vertigo—Doxorubicin—hematologic cancer	5.64e-05	9.61e-05	CcSEcCtD
Zuclopenthixol—Anorexia—Methotrexate—hematologic cancer	5.64e-05	9.61e-05	CcSEcCtD
Zuclopenthixol—Syncope—Doxorubicin—hematologic cancer	5.63e-05	9.59e-05	CcSEcCtD
Zuclopenthixol—Leukopenia—Doxorubicin—hematologic cancer	5.62e-05	9.57e-05	CcSEcCtD
Zuclopenthixol—Headache—Triamcinolone—hematologic cancer	5.62e-05	9.56e-05	CcSEcCtD
Zuclopenthixol—Abdominal pain—Prednisone—hematologic cancer	5.6e-05	9.53e-05	CcSEcCtD
Zuclopenthixol—Body temperature increased—Prednisone—hematologic cancer	5.6e-05	9.53e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Betamethasone—hematologic cancer	5.57e-05	9.47e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Dexamethasone—hematologic cancer	5.57e-05	9.47e-05	CcSEcCtD
Zuclopenthixol—Palpitations—Doxorubicin—hematologic cancer	5.55e-05	9.45e-05	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Epirubicin—hematologic cancer	5.54e-05	9.43e-05	CcSEcCtD
Zuclopenthixol—Hypotension—Methotrexate—hematologic cancer	5.53e-05	9.42e-05	CcSEcCtD
Zuclopenthixol—Loss of consciousness—Doxorubicin—hematologic cancer	5.52e-05	9.4e-05	CcSEcCtD
Zuclopenthixol—Shock—Epirubicin—hematologic cancer	5.45e-05	9.28e-05	CcSEcCtD
Zuclopenthixol—Convulsion—Doxorubicin—hematologic cancer	5.44e-05	9.26e-05	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Epirubicin—hematologic cancer	5.43e-05	9.25e-05	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Epirubicin—hematologic cancer	5.43e-05	9.23e-05	CcSEcCtD
Zuclopenthixol—Hypertension—Doxorubicin—hematologic cancer	5.42e-05	9.23e-05	CcSEcCtD
Zuclopenthixol—Tachycardia—Epirubicin—hematologic cancer	5.41e-05	9.2e-05	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	5.4e-05	9.18e-05	CcSEcCtD
Zuclopenthixol—Skin disorder—Epirubicin—hematologic cancer	5.38e-05	9.16e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Betamethasone—hematologic cancer	5.38e-05	9.16e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Dexamethasone—hematologic cancer	5.38e-05	9.16e-05	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Epirubicin—hematologic cancer	5.36e-05	9.12e-05	CcSEcCtD
Zuclopenthixol—Insomnia—Methotrexate—hematologic cancer	5.36e-05	9.12e-05	CcSEcCtD
Zuclopenthixol—Myalgia—Doxorubicin—hematologic cancer	5.35e-05	9.1e-05	CcSEcCtD
Zuclopenthixol—Anxiety—Doxorubicin—hematologic cancer	5.33e-05	9.07e-05	CcSEcCtD
Zuclopenthixol—Nausea—Triamcinolone—hematologic cancer	5.33e-05	9.06e-05	CcSEcCtD
Zuclopenthixol—Paraesthesia—Methotrexate—hematologic cancer	5.32e-05	9.05e-05	CcSEcCtD
Zuclopenthixol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	5.31e-05	9.04e-05	CcSEcCtD
Zuclopenthixol—Discomfort—Doxorubicin—hematologic cancer	5.28e-05	8.99e-05	CcSEcCtD
Zuclopenthixol—Anorexia—Epirubicin—hematologic cancer	5.28e-05	8.99e-05	CcSEcCtD
Zuclopenthixol—Dyspnoea—Methotrexate—hematologic cancer	5.28e-05	8.99e-05	CcSEcCtD
Zuclopenthixol—Somnolence—Methotrexate—hematologic cancer	5.26e-05	8.96e-05	CcSEcCtD
Zuclopenthixol—Dry mouth—Doxorubicin—hematologic cancer	5.23e-05	8.9e-05	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Prednisone—hematologic cancer	5.22e-05	8.88e-05	CcSEcCtD
Zuclopenthixol—Dyspepsia—Methotrexate—hematologic cancer	5.21e-05	8.87e-05	CcSEcCtD
Zuclopenthixol—Hypotension—Epirubicin—hematologic cancer	5.18e-05	8.81e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Dexamethasone—hematologic cancer	5.17e-05	8.8e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Betamethasone—hematologic cancer	5.17e-05	8.8e-05	CcSEcCtD
Zuclopenthixol—Decreased appetite—Methotrexate—hematologic cancer	5.15e-05	8.76e-05	CcSEcCtD
Zuclopenthixol—Rash—Betamethasone—hematologic cancer	5.13e-05	8.73e-05	CcSEcCtD
Zuclopenthixol—Rash—Dexamethasone—hematologic cancer	5.13e-05	8.73e-05	CcSEcCtD
Zuclopenthixol—Anaphylactic shock—Doxorubicin—hematologic cancer	5.13e-05	8.73e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Dexamethasone—hematologic cancer	5.13e-05	8.72e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Betamethasone—hematologic cancer	5.13e-05	8.72e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Methotrexate—hematologic cancer	5.11e-05	8.7e-05	CcSEcCtD
Zuclopenthixol—Fatigue—Methotrexate—hematologic cancer	5.11e-05	8.69e-05	CcSEcCtD
Zuclopenthixol—Headache—Dexamethasone—hematologic cancer	5.1e-05	8.67e-05	CcSEcCtD
Zuclopenthixol—Headache—Betamethasone—hematologic cancer	5.1e-05	8.67e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Prednisone—hematologic cancer	5.08e-05	8.65e-05	CcSEcCtD
Zuclopenthixol—Pain—Methotrexate—hematologic cancer	5.06e-05	8.62e-05	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	5.05e-05	8.59e-05	CcSEcCtD
Zuclopenthixol—Shock—Doxorubicin—hematologic cancer	5.04e-05	8.59e-05	CcSEcCtD
Zuclopenthixol—Nervous system disorder—Doxorubicin—hematologic cancer	5.03e-05	8.56e-05	CcSEcCtD
Zuclopenthixol—Thrombocytopenia—Doxorubicin—hematologic cancer	5.02e-05	8.54e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Prednisone—hematologic cancer	5.01e-05	8.53e-05	CcSEcCtD
Zuclopenthixol—Insomnia—Epirubicin—hematologic cancer	5.01e-05	8.53e-05	CcSEcCtD
Zuclopenthixol—Tachycardia—Doxorubicin—hematologic cancer	5e-05	8.52e-05	CcSEcCtD
Zuclopenthixol—Skin disorder—Doxorubicin—hematologic cancer	4.98e-05	8.48e-05	CcSEcCtD
Zuclopenthixol—Paraesthesia—Epirubicin—hematologic cancer	4.98e-05	8.47e-05	CcSEcCtD
Zuclopenthixol—Hyperhidrosis—Doxorubicin—hematologic cancer	4.96e-05	8.44e-05	CcSEcCtD
Zuclopenthixol—Dyspnoea—Epirubicin—hematologic cancer	4.94e-05	8.41e-05	CcSEcCtD
Zuclopenthixol—Somnolence—Epirubicin—hematologic cancer	4.93e-05	8.38e-05	CcSEcCtD
Zuclopenthixol—Anorexia—Doxorubicin—hematologic cancer	4.89e-05	8.32e-05	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Methotrexate—hematologic cancer	4.88e-05	8.3e-05	CcSEcCtD
Zuclopenthixol—Dyspepsia—Epirubicin—hematologic cancer	4.88e-05	8.3e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Prednisone—hematologic cancer	4.85e-05	8.25e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Methotrexate—hematologic cancer	4.84e-05	8.24e-05	CcSEcCtD
Zuclopenthixol—Nausea—Dexamethasone—hematologic cancer	4.83e-05	8.23e-05	CcSEcCtD
Zuclopenthixol—Nausea—Betamethasone—hematologic cancer	4.83e-05	8.23e-05	CcSEcCtD
Zuclopenthixol—Decreased appetite—Epirubicin—hematologic cancer	4.82e-05	8.2e-05	CcSEcCtD
Zuclopenthixol—Hypotension—Doxorubicin—hematologic cancer	4.79e-05	8.15e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Epirubicin—hematologic cancer	4.78e-05	8.14e-05	CcSEcCtD
Zuclopenthixol—Fatigue—Epirubicin—hematologic cancer	4.78e-05	8.13e-05	CcSEcCtD
Zuclopenthixol—Pain—Epirubicin—hematologic cancer	4.74e-05	8.07e-05	CcSEcCtD
Zuclopenthixol—Constipation—Epirubicin—hematologic cancer	4.74e-05	8.07e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Prednisone—hematologic cancer	4.69e-05	7.97e-05	CcSEcCtD
Zuclopenthixol—Abdominal pain—Methotrexate—hematologic cancer	4.68e-05	7.97e-05	CcSEcCtD
Zuclopenthixol—Body temperature increased—Methotrexate—hematologic cancer	4.68e-05	7.97e-05	CcSEcCtD
Zuclopenthixol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	4.67e-05	7.95e-05	CcSEcCtD
Zuclopenthixol—Insomnia—Doxorubicin—hematologic cancer	4.64e-05	7.89e-05	CcSEcCtD
Zuclopenthixol—Paraesthesia—Doxorubicin—hematologic cancer	4.6e-05	7.84e-05	CcSEcCtD
Zuclopenthixol—Dyspnoea—Doxorubicin—hematologic cancer	4.57e-05	7.78e-05	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Epirubicin—hematologic cancer	4.57e-05	7.77e-05	CcSEcCtD
Zuclopenthixol—Somnolence—Doxorubicin—hematologic cancer	4.56e-05	7.76e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Epirubicin—hematologic cancer	4.53e-05	7.71e-05	CcSEcCtD
Zuclopenthixol—Dyspepsia—Doxorubicin—hematologic cancer	4.51e-05	7.68e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Prednisone—hematologic cancer	4.51e-05	7.67e-05	CcSEcCtD
Zuclopenthixol—Rash—Prednisone—hematologic cancer	4.47e-05	7.6e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Prednisone—hematologic cancer	4.46e-05	7.6e-05	CcSEcCtD
Zuclopenthixol—Decreased appetite—Doxorubicin—hematologic cancer	4.46e-05	7.59e-05	CcSEcCtD
Zuclopenthixol—Headache—Prednisone—hematologic cancer	4.44e-05	7.55e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	4.43e-05	7.53e-05	CcSEcCtD
Zuclopenthixol—Fatigue—Doxorubicin—hematologic cancer	4.42e-05	7.52e-05	CcSEcCtD
Zuclopenthixol—Pain—Doxorubicin—hematologic cancer	4.38e-05	7.46e-05	CcSEcCtD
Zuclopenthixol—Constipation—Doxorubicin—hematologic cancer	4.38e-05	7.46e-05	CcSEcCtD
Zuclopenthixol—Body temperature increased—Epirubicin—hematologic cancer	4.38e-05	7.46e-05	CcSEcCtD
Zuclopenthixol—Abdominal pain—Epirubicin—hematologic cancer	4.38e-05	7.46e-05	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Methotrexate—hematologic cancer	4.36e-05	7.43e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Methotrexate—hematologic cancer	4.25e-05	7.23e-05	CcSEcCtD
Zuclopenthixol—Feeling abnormal—Doxorubicin—hematologic cancer	4.23e-05	7.19e-05	CcSEcCtD
Zuclopenthixol—Nausea—Prednisone—hematologic cancer	4.21e-05	7.16e-05	CcSEcCtD
Zuclopenthixol—Gastrointestinal pain—Doxorubicin—hematologic cancer	4.19e-05	7.14e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Methotrexate—hematologic cancer	4.19e-05	7.13e-05	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Epirubicin—hematologic cancer	4.08e-05	6.95e-05	CcSEcCtD
Zuclopenthixol—Body temperature increased—Doxorubicin—hematologic cancer	4.05e-05	6.9e-05	CcSEcCtD
Zuclopenthixol—Abdominal pain—Doxorubicin—hematologic cancer	4.05e-05	6.9e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Methotrexate—hematologic cancer	4.05e-05	6.9e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Epirubicin—hematologic cancer	3.98e-05	6.77e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Epirubicin—hematologic cancer	3.92e-05	6.67e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Methotrexate—hematologic cancer	3.92e-05	6.66e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Epirubicin—hematologic cancer	3.79e-05	6.45e-05	CcSEcCtD
Zuclopenthixol—Hypersensitivity—Doxorubicin—hematologic cancer	3.78e-05	6.43e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Methotrexate—hematologic cancer	3.77e-05	6.41e-05	CcSEcCtD
Zuclopenthixol—Rash—Methotrexate—hematologic cancer	3.73e-05	6.35e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Methotrexate—hematologic cancer	3.73e-05	6.35e-05	CcSEcCtD
Zuclopenthixol—Headache—Methotrexate—hematologic cancer	3.71e-05	6.31e-05	CcSEcCtD
Zuclopenthixol—Asthenia—Doxorubicin—hematologic cancer	3.68e-05	6.26e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Epirubicin—hematologic cancer	3.66e-05	6.24e-05	CcSEcCtD
Zuclopenthixol—Pruritus—Doxorubicin—hematologic cancer	3.63e-05	6.17e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Epirubicin—hematologic cancer	3.52e-05	6e-05	CcSEcCtD
Zuclopenthixol—Nausea—Methotrexate—hematologic cancer	3.52e-05	5.99e-05	CcSEcCtD
Zuclopenthixol—Diarrhoea—Doxorubicin—hematologic cancer	3.51e-05	5.97e-05	CcSEcCtD
Zuclopenthixol—Rash—Epirubicin—hematologic cancer	3.49e-05	5.95e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Epirubicin—hematologic cancer	3.49e-05	5.94e-05	CcSEcCtD
Zuclopenthixol—Headache—Epirubicin—hematologic cancer	3.47e-05	5.91e-05	CcSEcCtD
Zuclopenthixol—Dizziness—Doxorubicin—hematologic cancer	3.39e-05	5.77e-05	CcSEcCtD
Zuclopenthixol—Nausea—Epirubicin—hematologic cancer	3.29e-05	5.6e-05	CcSEcCtD
Zuclopenthixol—Vomiting—Doxorubicin—hematologic cancer	3.26e-05	5.55e-05	CcSEcCtD
Zuclopenthixol—Rash—Doxorubicin—hematologic cancer	3.23e-05	5.5e-05	CcSEcCtD
Zuclopenthixol—Dermatitis—Doxorubicin—hematologic cancer	3.23e-05	5.5e-05	CcSEcCtD
Zuclopenthixol—Headache—Doxorubicin—hematologic cancer	3.21e-05	5.47e-05	CcSEcCtD
Zuclopenthixol—Nausea—Doxorubicin—hematologic cancer	3.05e-05	5.18e-05	CcSEcCtD
Zuclopenthixol—DRD1—Signaling Pathways—CCND1—hematologic cancer	8.49e-06	5.93e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—JUN—hematologic cancer	8.47e-06	5.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—BRAF—hematologic cancer	8.46e-06	5.92e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—TP53—hematologic cancer	8.41e-06	5.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCL2—hematologic cancer	8.38e-06	5.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CD80—hematologic cancer	8.38e-06	5.86e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CG—hematologic cancer	8.36e-06	5.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KIT—hematologic cancer	8.36e-06	5.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—NRAS—hematologic cancer	8.36e-06	5.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6R—hematologic cancer	8.36e-06	5.84e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CREBBP—hematologic cancer	8.34e-06	5.83e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3R1—hematologic cancer	8.3e-06	5.8e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAP2K1—hematologic cancer	8.27e-06	5.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTPN11—hematologic cancer	8.22e-06	5.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CD—hematologic cancer	8.21e-06	5.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—CDKN1A—hematologic cancer	8.21e-06	5.74e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PTEN—hematologic cancer	8.19e-06	5.73e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—PIK3CA—hematologic cancer	8.13e-06	5.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAP2K1—hematologic cancer	8.13e-06	5.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MAPK3—hematologic cancer	8.13e-06	5.69e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAP2K1—hematologic cancer	8.12e-06	5.68e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CD—hematologic cancer	8.08e-06	5.65e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CD—hematologic cancer	8.06e-06	5.64e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—HRAS—hematologic cancer	8.05e-06	5.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—KRAS—hematologic cancer	8.04e-06	5.62e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK8—hematologic cancer	8.01e-06	5.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—MAPK3—hematologic cancer	8.01e-06	5.6e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—PIK3CA—hematologic cancer	8e-06	5.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling by GPCR—AKT1—hematologic cancer	7.99e-06	5.59e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.99e-06	5.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAP2K1—hematologic cancer	7.96e-06	5.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CREB1—hematologic cancer	7.96e-06	5.57e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CD—hematologic cancer	7.91e-06	5.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—KRAS—hematologic cancer	7.91e-06	5.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—MYC—hematologic cancer	7.91e-06	5.53e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—KRAS—hematologic cancer	7.89e-06	5.52e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TGFB1—hematologic cancer	7.89e-06	5.52e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—FGF2—hematologic cancer	7.86e-06	5.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—BRAF—hematologic cancer	7.86e-06	5.5e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—PIK3CA—hematologic cancer	7.84e-06	5.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—EP300—hematologic cancer	7.81e-06	5.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCL2—hematologic cancer	7.79e-06	5.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6R—hematologic cancer	7.76e-06	5.43e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—MTHFR—hematologic cancer	7.76e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3R1—hematologic cancer	7.75e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CREBBP—hematologic cancer	7.75e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—KRAS—hematologic cancer	7.75e-06	5.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—FGF2—hematologic cancer	7.74e-06	5.41e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—FGF2—hematologic cancer	7.72e-06	5.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—IL6—hematologic cancer	7.7e-06	5.39e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CB—hematologic cancer	7.66e-06	5.36e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3R1—hematologic cancer	7.63e-06	5.34e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3R1—hematologic cancer	7.61e-06	5.32e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—SRC—hematologic cancer	7.6e-06	5.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—FGF2—hematologic cancer	7.58e-06	5.3e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JAK2—hematologic cancer	7.54e-06	5.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3R1—hematologic cancer	7.47e-06	5.22e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JAK2—hematologic cancer	7.42e-06	5.19e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAP2K1—hematologic cancer	7.4e-06	5.17e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JAK2—hematologic cancer	7.4e-06	5.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—VEGFA—hematologic cancer	7.4e-06	5.17e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—PIK3CA—hematologic cancer	7.39e-06	5.16e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MDM2—hematologic cancer	7.36e-06	5.14e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CD—hematologic cancer	7.35e-06	5.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—STAT3—hematologic cancer	7.33e-06	5.12e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—NRAS—hematologic cancer	7.31e-06	5.11e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—KRAS—hematologic cancer	7.31e-06	5.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	7.28e-06	5.09e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—PIK3CA—hematologic cancer	7.27e-06	5.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JAK2—hematologic cancer	7.26e-06	5.08e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—PIK3CA—hematologic cancer	7.25e-06	5.07e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MDM2—hematologic cancer	7.24e-06	5.06e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MDM2—hematologic cancer	7.22e-06	5.05e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—KRAS—hematologic cancer	7.2e-06	5.03e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MTOR—hematologic cancer	7.16e-06	5.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CB—hematologic cancer	7.16e-06	5.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—PIK3CA—hematologic cancer	7.12e-06	4.98e-05	CbGpPWpGaD
Zuclopenthixol—DRD5—Signaling Pathways—AKT1—hematologic cancer	7.11e-06	4.97e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MDM2—hematologic cancer	7.09e-06	4.96e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MTOR—hematologic cancer	7.04e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CB—hematologic cancer	7.04e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—FGF2—hematologic cancer	7.04e-06	4.92e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MTOR—hematologic cancer	7.03e-06	4.91e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CB—hematologic cancer	7.03e-06	4.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MAPK3—hematologic cancer	7e-06	4.89e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3R1—hematologic cancer	6.94e-06	4.85e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CB—hematologic cancer	6.9e-06	4.82e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MTOR—hematologic cancer	6.9e-06	4.82e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—HRAS—hematologic cancer	6.83e-06	4.78e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—MYC—hematologic cancer	6.81e-06	4.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TGFB1—hematologic cancer	6.79e-06	4.75e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JAK2—hematologic cancer	6.75e-06	4.72e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—HRAS—hematologic cancer	6.72e-06	4.7e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1B—hematologic cancer	6.72e-06	4.7e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—PIK3CA—hematologic cancer	6.71e-06	4.69e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—HRAS—hematologic cancer	6.71e-06	4.69e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—GPCR downstream signaling—AKT1—hematologic cancer	6.64e-06	4.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PTEN—hematologic cancer	6.62e-06	4.63e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—PIK3CA—hematologic cancer	6.61e-06	4.62e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1B—hematologic cancer	6.61e-06	4.62e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1B—hematologic cancer	6.6e-06	4.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MDM2—hematologic cancer	6.59e-06	4.61e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—HRAS—hematologic cancer	6.58e-06	4.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CASP3—hematologic cancer	6.58e-06	4.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL2—hematologic cancer	6.57e-06	4.6e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—IL6—hematologic cancer	6.54e-06	4.57e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—GPCR downstream signaling—AKT1—hematologic cancer	6.54e-06	4.57e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—GPCR downstream signaling—AKT1—hematologic cancer	6.52e-06	4.56e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	6.52e-06	4.56e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—TP53—hematologic cancer	6.49e-06	4.54e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CASP3—hematologic cancer	6.48e-06	4.53e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1B—hematologic cancer	6.47e-06	4.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL2—hematologic cancer	6.47e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CASP3—hematologic cancer	6.46e-06	4.52e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL2—hematologic cancer	6.45e-06	4.51e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—IL6—hematologic cancer	6.44e-06	4.5e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—IL6—hematologic cancer	6.42e-06	4.49e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CCND1—hematologic cancer	6.41e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MTOR—hematologic cancer	6.41e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CB—hematologic cancer	6.41e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—GPCR downstream signaling—AKT1—hematologic cancer	6.4e-06	4.48e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—JUN—hematologic cancer	6.39e-06	4.47e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CASP3—hematologic cancer	6.34e-06	4.44e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL2—hematologic cancer	6.33e-06	4.43e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—EP300—hematologic cancer	6.31e-06	4.42e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CCND1—hematologic cancer	6.31e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—IL6—hematologic cancer	6.3e-06	4.41e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—JUN—hematologic cancer	6.29e-06	4.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CCND1—hematologic cancer	6.29e-06	4.4e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—KRAS—hematologic cancer	6.29e-06	4.4e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—JUN—hematologic cancer	6.28e-06	4.39e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—HRAS—hematologic cancer	6.21e-06	4.34e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—CDKN1A—hematologic cancer	6.2e-06	4.33e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PTEN—hematologic cancer	6.19e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CCND1—hematologic cancer	6.17e-06	4.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—JUN—hematologic cancer	6.16e-06	4.31e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—HRAS—hematologic cancer	6.12e-06	4.28e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—CDKN1A—hematologic cancer	6.1e-06	4.27e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—CDKN1A—hematologic cancer	6.09e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PTEN—hematologic cancer	6.09e-06	4.26e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PTEN—hematologic cancer	6.07e-06	4.25e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK8—hematologic cancer	6.05e-06	4.23e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—CREBBP—hematologic cancer	6.04e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling by GPCR—AKT1—hematologic cancer	6.03e-06	4.22e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1B—hematologic cancer	6.01e-06	4.2e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—CDKN1A—hematologic cancer	5.97e-06	4.18e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PTEN—hematologic cancer	5.96e-06	4.17e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK8—hematologic cancer	5.95e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—GPCR downstream signaling—AKT1—hematologic cancer	5.95e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—IL6—hematologic cancer	5.95e-06	4.16e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK8—hematologic cancer	5.94e-06	4.15e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling by GPCR—AKT1—hematologic cancer	5.94e-06	4.15e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling by GPCR—AKT1—hematologic cancer	5.92e-06	4.14e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—EP300—hematologic cancer	5.9e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CASP3—hematologic cancer	5.89e-06	4.12e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL2—hematologic cancer	5.88e-06	4.11e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—IL6—hematologic cancer	5.86e-06	4.09e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK8—hematologic cancer	5.83e-06	4.08e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling by GPCR—AKT1—hematologic cancer	5.81e-06	4.07e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—EP300—hematologic cancer	5.8e-06	4.06e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—EP300—hematologic cancer	5.79e-06	4.05e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—PIK3CA—hematologic cancer	5.78e-06	4.04e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CCND1—hematologic cancer	5.74e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—SRC—hematologic cancer	5.74e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	5.73e-06	4.01e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—JUN—hematologic cancer	5.72e-06	4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—EP300—hematologic cancer	5.68e-06	3.97e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—ALB—hematologic cancer	5.66e-06	3.95e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—SRC—hematologic cancer	5.64e-06	3.95e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—SRC—hematologic cancer	5.63e-06	3.94e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—TP53—hematologic cancer	5.59e-06	3.91e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—VEGFA—hematologic cancer	5.59e-06	3.91e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—CDKN1A—hematologic cancer	5.55e-06	3.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PTEN—hematologic cancer	5.54e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—STAT3—hematologic cancer	5.53e-06	3.87e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—SRC—hematologic cancer	5.53e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—NRAS—hematologic cancer	5.52e-06	3.86e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—VEGFA—hematologic cancer	5.5e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—VEGFA—hematologic cancer	5.49e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR6—Signaling Pathways—AKT1—hematologic cancer	5.48e-06	3.84e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—STAT3—hematologic cancer	5.44e-06	3.81e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—STAT3—hematologic cancer	5.43e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—NRAS—hematologic cancer	5.43e-06	3.8e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—NRAS—hematologic cancer	5.42e-06	3.79e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK8—hematologic cancer	5.42e-06	3.79e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	5.41e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling by GPCR—AKT1—hematologic cancer	5.4e-06	3.78e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—VEGFA—hematologic cancer	5.38e-06	3.76e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—HRAS—hematologic cancer	5.35e-06	3.74e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—STAT3—hematologic cancer	5.33e-06	3.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—NRAS—hematologic cancer	5.32e-06	3.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MAPK3—hematologic cancer	5.28e-06	3.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—EP300—hematologic cancer	5.28e-06	3.69e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MAPK3—hematologic cancer	5.2e-06	3.64e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MAPK3—hematologic cancer	5.19e-06	3.63e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—MYC—hematologic cancer	5.14e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—SRC—hematologic cancer	5.13e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TGFB1—hematologic cancer	5.13e-06	3.59e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—IL6—hematologic cancer	5.12e-06	3.58e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MAPK3—hematologic cancer	5.09e-06	3.56e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—MYC—hematologic cancer	5.06e-06	3.54e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—MYC—hematologic cancer	5.05e-06	3.53e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TGFB1—hematologic cancer	5.05e-06	3.53e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TGFB1—hematologic cancer	5.03e-06	3.52e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—VEGFA—hematologic cancer	5e-06	3.5e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	4.99e-06	3.49e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—MYC—hematologic cancer	4.95e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—STAT3—hematologic cancer	4.95e-06	3.46e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TGFB1—hematologic cancer	4.94e-06	3.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—NRAS—hematologic cancer	4.94e-06	3.45e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—KRAS—hematologic cancer	4.75e-06	3.32e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MAPK3—hematologic cancer	4.73e-06	3.31e-05	CbGpPWpGaD
Zuclopenthixol—DRD1—Signaling Pathways—AKT1—hematologic cancer	4.72e-06	3.3e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—KRAS—hematologic cancer	4.67e-06	3.27e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—PIK3CA—hematologic cancer	4.67e-06	3.27e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—KRAS—hematologic cancer	4.66e-06	3.26e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—MYC—hematologic cancer	4.6e-06	3.22e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TGFB1—hematologic cancer	4.59e-06	3.21e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—KRAS—hematologic cancer	4.58e-06	3.2e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—PIK3CA—hematologic cancer	4.36e-06	3.05e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PTEN—hematologic cancer	4.31e-06	3.02e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—PIK3CA—hematologic cancer	4.29e-06	3e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—PIK3CA—hematologic cancer	4.28e-06	3e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—KRAS—hematologic cancer	4.25e-06	2.97e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—TP53—hematologic cancer	4.22e-06	2.95e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—PIK3CA—hematologic cancer	4.2e-06	2.94e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—TP53—hematologic cancer	4.15e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—TP53—hematologic cancer	4.14e-06	2.9e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—EP300—hematologic cancer	4.11e-06	2.88e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—TP53—hematologic cancer	4.07e-06	2.84e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—HRAS—hematologic cancer	4.04e-06	2.82e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—HRAS—hematologic cancer	3.97e-06	2.78e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—HRAS—hematologic cancer	3.96e-06	2.77e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—PIK3CA—hematologic cancer	3.91e-06	2.73e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—HRAS—hematologic cancer	3.89e-06	2.72e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—IL6—hematologic cancer	3.86e-06	2.7e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Metabolism—AKT1—hematologic cancer	3.82e-06	2.67e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—IL6—hematologic cancer	3.8e-06	2.66e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—IL6—hematologic cancer	3.79e-06	2.65e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—TP53—hematologic cancer	3.78e-06	2.64e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—IL6—hematologic cancer	3.72e-06	2.6e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—HRAS—hematologic cancer	3.61e-06	2.53e-05	CbGpPWpGaD
Zuclopenthixol—DRD2—Signaling Pathways—AKT1—hematologic cancer	3.56e-06	2.49e-05	CbGpPWpGaD
Zuclopenthixol—HTR2A—Signaling Pathways—AKT1—hematologic cancer	3.51e-06	2.45e-05	CbGpPWpGaD
Zuclopenthixol—HRH1—Signaling Pathways—AKT1—hematologic cancer	3.5e-06	2.45e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—IL6—hematologic cancer	3.46e-06	2.42e-05	CbGpPWpGaD
Zuclopenthixol—ADRA1A—Signaling Pathways—AKT1—hematologic cancer	3.43e-06	2.4e-05	CbGpPWpGaD
Zuclopenthixol—ADRA2A—Signaling Pathways—AKT1—hematologic cancer	3.19e-06	2.23e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	3.04e-06	2.13e-05	CbGpPWpGaD
Zuclopenthixol—CYP2D6—Metabolism—AKT1—hematologic cancer	2.49e-06	1.74e-05	CbGpPWpGaD
